跳至主要内容
临床试验/NCT01251900
NCT01251900已完成不适用

BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects

National Cancer Institute (NCI)1 个研究点 分布在 1 个国家目标入组 266 人开始时间: 2011年7月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
266
试验地点
1
主要终点
Collection of saliva from 2000 probands

研究概览

简要总结

Background:

- BRCA1 and BRCA2 gene mutations have been linked to a higher risk of developing breast cancer and other cancers, and may be associated with types of breast cancer that are more difficult to treat and more likely to recur. New cancer treatments are being developed specifically to treat individuals who have these gene mutations. However, more information is needed about the prevalence of these mutations in minority populations, including Hispanic/Latino populations. To study these populations, researchers are interested in collecting genetic material (DNA) and medical history information from Hispanic/Latino women who have been diagnosed with breast cancer.

Objectives:

- To collect saliva samples and medical and family history information from Hispanic/Latino women with breast cancer.

Eligibility:

- Hispanic/Latino women at least 18 years of age who have been diagnosed with breast cancer.

Design:

  • Participants will complete a questionnaire with information about place of birth, languages spoken by parents and grandparents, and information about their breast cancer diagnosis.
  • Participants will provide a saliva sample (2 to 3 tablespoons) for analysis.
  • No treatment will be provided as part of this protocol.

详细描述

BACKGROUND:

  • Mutations in the BRCA1 and BRCA2 genes predispose to breast and ovarian cancer, and are increasingly recognized in prostate and pancreatic cancers.
  • Basal/ Triple negative breast cancer is associated with BRCA mutations in some ethnicities.However the link between BRCA gene mutations and Basil/ triple negative disease in Hispanic/ Latino women is not known.
  • Common recurrent mutations in BRCA1 and BRCA2 exist in Hispanic/ Latino communities.
  • New therapies such as PARP inhibitors may be particularly effective in BRCA mutation carriers.
  • Therefore a unique opportunity exists to identify women in this underserved minority that may be eligible for and benefit from new targeted therapies.

OBJECTIVES:

- The primary objective is to collect saliva samples and histology data from up to 2000 Hispanic/ Latino subjects with breast cancer as a source of DNA, and to analyze the BRCA1 and BRCA2 genes..

ELIGIBILITY:

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • INCLUSION CRITERIA:
  • Patient must be self-identified of Hispanic/Latino origin.
  • Patients must have histologically or cytologically confirmed diagnosis of breast cancer.
  • Age greater than or equal to 18 years.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Must be willing and able to provide a saliva sample, answer questionnaire data online or complete a paper questionnaire, and request a copy of their pathology report.

排除标准

  • - Males and subjects under the age of 18.

研究组 & 干预措施

Patients

Hispanic women, over the age of 18, with breast cancer will be eligible.

结局指标

主要结局

Collection of saliva from 2000 probands

时间窗: Every six months

次要结局

未报告次要终点

研究者

申办方类型
Nih
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验